报价延迟最少15分钟:2026/04/14 16:39 EDT
盘后时段
|
||||
|
59.35 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
59.35
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.36/-5.68
|
|
企业价值
5.60B
|
| 资产负债 |
|
每股账面净值
6.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.50M
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
